In 2014, MAPS spun out a individual division to direct study and get ready for an eventual FDA application, which it submitted at the end of past year. In early 2024, that offshoot was renamed Lykos Therapeutics. So at the same time as blotter proceeds to stoke and replicate shopper and collector